Zymeworks Inc. insider trading
Every open-market purchase and sale by Zymeworks Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Zymeworks Inc.’s insiders pay?
From January 12, 2023 to October 9, 2026, 9 insiders reported 18 open-market purchases and 16 sales not made under a pre-set plan in Zymeworks Inc. Twelve months after each purchase was reported, the shares were +48.4% against the S&P 500 on average (median +61.1%), over 18 purchases with a full year of prices; 72% beat the index. After sales, the shares moved +13.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on January 13, 2023 into $14,960 by November 2, 2026, +11.2% a year. It held shares 74% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,580 (+17.8% a year), and held throughout $19,902 (+20.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Ecor1 Capital, LLC | Director | 16 | +41.8% (16) | 69% | 0 | — | May 19, 2025 |
| Galbraith Kenneth | Chair & CEO | 0 | — | — | 5 | +16.8% (2) | January 12, 2026 |
| Moore Paul Andrew | Chief Scientific Officer | 0 | — | — | 4 | +16.8% (2) | January 12, 2026 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 0 | — | — | 3 | +42.6% (1) | January 12, 2026 |
| Nodelman Oleg | Director | 2 | +101.4% (2) | 100% | 0 | — | April 7, 2025 |
| Astle Christopher | SVP & Chief Financial Officer | 0 | — | — | 1 | −9.1% (1) | January 8, 2024 |
| Hollywood Mark | EVP & Chief Operating Officer | 0 | — | — | 1 | — | January 13, 2026 |
| Klompas Neil A | President & COO | 0 | — | — | 1 | −8.1% (1) | March 14, 2023 |
| Schayowitz Adam | EVP, Head of R&D | 0 | — | — | 1 | — | October 9, 2026 |
When several insiders traded Zymeworks Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Zymeworks Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +24.3% against the index. After 3 selling crowds, −17.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 30, 2026 | 4 selling | +13.7% | −13.3% | not yet |
| April 30, 2025 | 2 buying | −17.8% | +24.3% | +73.1% |
| January 31, 2025 | 3 selling | −5.7% | −19.2% | +44.6% |
| January 31, 2024 | 3 selling | −23.1% | −19.9% | +10.2% |